Has Ashish Wadhwa, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,702 in general payments to Ashish Wadhwa, MD across 73 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ashish Wadhwa, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ashish Wadhwa, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ashish Wadhwa, MD

Otolaryngology · Poway, CANPI 1477595189

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $587 and has fallen 51.4% since, to $285 in 2025.

$2,702in general payments, 2019–2025

Across 73 payments — averaging $37.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$349
Inspire Medical Systems, Inc.$343
Stryker$324
Neurent Medical Limited$255
AstraZeneca$249
Regeneron Healthcare Solutions, Inc.$241
plus $942 from 16 others

What the payments were for

Food & beverage$2,68499%
Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	14	$349
Inspire Medical Systems, Inc.	6	$343
Stryker	10	$324
Neurent Medical Limited	3	$255
AstraZeneca	4	$249
Regeneron Healthcare Solutions, Inc.	6	$241
Biohaven Pharmaceuticals, Inc.	3	$157
Novartis	2	$121
Covidien LP	1	$111
Optinose US, Inc.	5	$95
Endogastric Solutions, Inc	1	$88
GSK	2	$61
Aerin Medical Inc.	3	$56
Alk-abello, Inc	2	$50
Intersect ENT, Inc.	2	$38
Acclarent, Inc	2	$37
Paratek Pharmaceuticals, Inc.	1	$27
Integra Lifesciences Corporation	1	$23
AbbVie	1	$20
Medtronic	1	$19
Travere Therapeutics, Inc.	2	$19
Hikma Pharmaceuticals USA	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,702 in reported general payments places this provider in the 70th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California →

Medicare billing

Part B allowed, 2024

$237,171

Medicare patients

367

Services billed

2,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fluticasone Propionate	157	$2,721
Azelastine-FluticasoneAzelastine/Fluticasone	16	$2,006
Ipratropium Bromide	70	$1,962
Azelastine Hcl	40	$1,525
Omeprazole	84	$579
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	61	$467
Montelukast Sodium	33	$458
Ofloxacin	15	$326
Methylprednisolone	43	$319
ValacyclovirValacyclovir Hcl	20	$292
Famotidine	20	$279
Azithromycin	50	$241
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	13	$59

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Poway

Brian WeeksSan Diego$924K
Randall OwRoseville$613K
Amir MoradiVista$389K
Keith BlackwellLos Angeles$349K
Kalpna DurairajSun Valley$348K
Todd MillerNewport Beach$259K
Jeffrey SuhLos Angeles$223K
Dennis TangLos Angeles$209K
Jeffrey FeinfieldThousand Oaks$160K
Jonathan SykesGranite Bay$148K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →